Clinical Trial Detail

NCT ID NCT02120417
Title A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Incyte Corporation
Indications

Her2-receptor negative breast cancer

Therapies

Capecitabine + Ruxolitinib

Capecitabine

Age Groups: adult

Additional content available in CKB BOOST